Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Azad Bonni

Showing results (121-130 of 131) with videos related to

Pageof 14
Sort By:
Parkinsonism & Related Disorders|January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline dataTania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled studyTania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, et al.
Nature Communications|December 3, 2020
Astrocyte deletion of α2-Na/K ATPase triggers episodic motor paralysis in mice via a metabolic pathwaySarah E Smith, Xiaoying Chen, Lindsey M Brier, et al.
Cell Reports|January 25, 2025
The Hao-Fountain syndrome protein USP7 regulates neuronal connectivity in the brain via a novel p53-independent ubiquitin signaling pathwayHao Chen, Cole J Ferguson, Dylan C Mitchell, et al.
Nature Medicine|July 11, 2025
The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trialJörg F Hipp, Carlos A Bacino, Lynne M Bird, et al.
Nucleic Acids Research|August 30, 2025
Angelman syndrome patient-derived neuron screen leads to clinical ASO rugonersen targeting UBE3A-ATS with long-lasting effect in monkeysRavi Jagasia, Charlotte Bon, Soren V Rasmussen, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Molecular Cell|December 23, 2021
APC7 mediates ubiquitin signaling in constitutive heterochromatin in the developing mammalian brainCole J Ferguson, Olivia Urso, Tatyana Bodrug, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Prasinezumab in Early-Stage Parkinson's DiseaseGennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 14

Showing results (121-130 of 131) with videos related to

Sort By:
Pageof 14
Parkinsonism & Related Disorders|January 11, 2025
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline dataTania Nikolcheva, Gennaro Pagano, Nathalie Pross, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled studyTania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, et al.
Nature Communications|December 3, 2020
Astrocyte deletion of α2-Na/K ATPase triggers episodic motor paralysis in mice via a metabolic pathwaySarah E Smith, Xiaoying Chen, Lindsey M Brier, et al.
Cell Reports|January 25, 2025
The Hao-Fountain syndrome protein USP7 regulates neuronal connectivity in the brain via a novel p53-independent ubiquitin signaling pathwayHao Chen, Cole J Ferguson, Dylan C Mitchell, et al.
Nature Medicine|July 11, 2025
The UBE3A-ATS antisense oligonucleotide rugonersen in children with Angelman syndrome: a phase 1 trialJörg F Hipp, Carlos A Bacino, Lynne M Bird, et al.
Nucleic Acids Research|August 30, 2025
Angelman syndrome patient-derived neuron screen leads to clinical ASO rugonersen targeting UBE3A-ATS with long-lasting effect in monkeysRavi Jagasia, Charlotte Bon, Soren V Rasmussen, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Molecular Cell|December 23, 2021
APC7 mediates ubiquitin signaling in constitutive heterochromatin in the developing mammalian brainCole J Ferguson, Olivia Urso, Tatyana Bodrug, et al.
The New England Journal of Medicine|August 3, 2022
Trial of Prasinezumab in Early-Stage Parkinson's DiseaseGennaro Pagano, Kirsten I Taylor, Judith Anzures-Cabrera, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 14